Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02934464
Title Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers (ARMANI)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma


Paclitaxel + Ramucirumab

Fluorouracil + Leucovorin + Oxaliplatin

Capecitabine + Oxaliplatin

Age Groups: adult | senior
Covered Countries ITA

No variant requirements are available.